Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (Q39408906)
Jump to navigation
Jump to search
scientific article published on 5 September 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial |
scientific article published on 5 September 2016 |
Statements
1 reference
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (English)
1 reference
William W Busse
1 reference
Eugene R Bleecker
1 reference
J Mark FitzGerald
1 reference
Parameswaran Nair
1 reference
Stephanie Korn
1 reference
Ken Ohta
1 reference
Marek Lommatzsch
1 reference
Gary T Ferguson
1 reference
Peter Barker
1 reference
Stephanie Sproule
1 reference
Geoffrey Gilmartin
1 reference
Viktoria Werkström
1 reference
Magnus Aurivillius
1 reference
Mitchell Goldman
1 reference
CALIMA study investigators
1 reference
5 September 2016
1 reference
1 reference
388
1 reference
10056
1 reference
2128-2141
1 reference
Identifiers
1 reference
1 reference